Last update 13 Dec 2024

Ivonescimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
ivonescimab, AK 112, AK-112
+ [4]
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Priority Review (CN), Breakthrough Therapy (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancer
CN
21 May 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Non-Small Cell Lung CancerNDA/BLA
CN
27 Jul 2024
PD-L1 positive Non-Small Cell Lung CancerNDA/BLA
CN
27 Jul 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
CN
31 Oct 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
CN
31 Oct 2024
Advanced Bile Duct CarcinomaPhase 3
CN
01 Oct 2024
Unresectable Biliary Tract CarcinomaPhase 3
CN
01 Oct 2024
Advanced biliary tract cancerPhase 3
CN
25 Aug 2024
Squamous non-small cell lung cancerPhase 3
CN
28 Jul 2023
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CN
25 Jan 2022
Hepatocellular CarcinomaPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Colorectal Carcinoma
First line
KRAS | BRAF | MSS
40
FOLFOXIRI + Ivonescimab
vkxdcvybir(nrzyhhrnkh) = bycwijbpkv jamwhgbkbl (awdxzdrmjz )
Positive
14 Sep 2024
FOLFOXIRI + Ivonescimab + Ligufalimab
vkxdcvybir(nrzyhhrnkh) = tbjdjpwuzr jamwhgbkbl (awdxzdrmjz )
Phase 3
398
Ivonescimab 20 mg/kg
emnaikqvtx(jrplukntnu) = sizvuktsyi eoxivmsgip (vdglcyclxz )
Positive
08 Sep 2024
emnaikqvtx(jrplukntnu) = kgrbyupmxc eoxivmsgip (vdglcyclxz )
Phase 3
398
ogqceseezw(qgyjzjfrmj) = 在意向治疗人群(ITT)中,依沃西组相较于帕博利珠组显著延长了患者无进展生存期(PFS),风险比(HR)显著优于预期 htyyohuzbp (kboaffjnww )
Met
Superior
31 May 2024
Phase 1
Non-Small Cell Lung Cancer
First line
programmed death ligand-1 tumor proportion score (TPS)
108
Ivonescimab 10 mg/kg Q3W
mwmtxmfwoo(dpsktgsihz) = nmbjakyzzb xcscxqnulc (ogivlxirqa )
Positive
01 Mar 2024
(TPS less than 1%)
mwmtxmfwoo(dpsktgsihz) = upuwvzykdt xcscxqnulc (ogivlxirqa )
Phase 3
-
dvpzdhaqvn(yaztgfbkgx) = Safety tolerable, no new safety signal observed. giakysjrtv (qnahkiayxs )
Positive
31 Oct 2022
Phase 1
29
kmvijsupdt(hisapvzypz) = None bltowisded (uqnoslktfx )
Positive
28 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free